Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis.[5] It is designed to attach to interleukin-23 (IL-23) and block its activity.[5]
The most common side effects include upper respiratory tract infections (nose and throat infections), headache, rash and reactions at the site of injection (when given by injection under the skin).[5]
Mirikizumab was approved for medical use in the European Union in May 2023,[5] and in the United States in October 2023.[7][8][9]
^ ab"Omvoh APMDS". Therapeutic Goods Administration (TGA). 11 October 2023. Archived from the original on 2 January 2024. Retrieved 7 March 2024.
^"Details for: Omvoh". Drug and Health Products Portal. 5 December 2023. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
^"Notice: Multiple additions to the Prescription Drug List (PDL) [2023-10-26]". Health Canada. 26 October 2023. Archived from the original on 3 January 2024. Retrieved 3 January 2024.
^"Omvoh- mirikizumab-mrkz injection, solution". DailyMed. 31 October 2023. Archived from the original on 8 November 2023. Retrieved 8 November 2023.
^ abcde"Omvoh EPAR". European Medicines Agency. 8 June 2023. Archived from the original on 8 June 2023. Retrieved 8 June 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^"Omvoh". Union Register of medicinal products. 30 May 2023. Retrieved 6 June 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^"Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 26 October 2023. Archived from the original on 21 January 2023. Retrieved 30 October 2023.
^"Eli Lilly's Omvoh granted FDA approval for ulcerative colitis". PMLive. 27 October 2023. Archived from the original on 30 October 2023. Retrieved 30 October 2023.
^"FDA Approves Lilly's Omvoh (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis" (Press release). Eli Lilly and Company. Archived from the original on 30 October 2023. Retrieved 30 October 2023 – via PR Newswire.
Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis. It is designed to attach to interleukin-23...
blocked by the biologic ustekinumab and IL-23 is blocked by guselkumab, mirikizumab and risankizumab, medications that are used in the treatment of ulcerative...